Cannabidiol and cannabigerol, non-psychotropic cannabinoids, as analgesics that effectively manage bone fracture pain and promote healing in mice.
Deepak Kumar KhajuriaVengadeshprabhu KaruppagounderIrena NowakDiana E SepulvedaGregory S LewisChristopher Norbury CWesley M Raup-KonsavageKent E VranaFadia KamalReyad A ElbarbaryPublished in: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research (2023)
Bone fractures are among the most prevalent musculoskeletal injuries, and pain management is an essential part of fracture treatment. Fractures heal through an early inflammatory phase, followed by repair and remodelling. Nonsteroidal anti-inflammatory drugs (NSAIDs) are not recommended for fracture pain control as they potently inhibit the inflammatory phase and, thus, impair the healing. Opioids do not provide a better alternative for several reasons, including abuse potential. Accordingly, there is an unmet clinical need for analgesics that effectively ameliorate post-fracture pain without impeding the healing. Here, we investigated the analgesic efficacy of two non-psychotropic cannabinoids, cannabidiol (CBD) and cannabigerol (CBG), in a mouse model for tibial fracture. Mice with fractured tibiae exhibited increased sensitivity to mechanical, cold, and hot stimuli. Both CBD and CBG normalized pain sensitivity to all tested stimuli, and their analgesic effects were comparable to those of the NSAIDs. Interestingly, CBD and CBG promoted bone healing via multiple mechanisms during the early and late phases. During the early inflammatory phase, both cannabinoids increased the abundance of periosteal bone progenitors in the healing hematoma and promoted the osteogenic commitment of these progenitors. During the later phases of healing, CBD and CBG accelerated the fibrocartilaginous callus mineralization and enhanced the viability and proliferation of bone and bone-marrow cells. These effects culminated in higher bone volume fraction, higher bone mineral density, and improved mechanical quality of the newly formed bone. Together, our data suggest CBD and CBG as therapeutic agents that can replace NSAIDs in managing post-fracture pain as both cannabinoids exert potent analgesic effects and, at the same time, promote bone healing. This article is protected by copyright. All rights reserved.
Keyphrases
- bone mineral density
- pain management
- chronic pain
- postmenopausal women
- neuropathic pain
- body composition
- bone marrow
- soft tissue
- anti inflammatory drugs
- mouse model
- bone loss
- bone regeneration
- mesenchymal stem cells
- hip fracture
- total knee arthroplasty
- anti inflammatory
- spinal cord
- cell death
- signaling pathway
- machine learning
- mass spectrometry
- electronic health record
- induced apoptosis
- big data
- adipose tissue
- endoplasmic reticulum stress
- smoking cessation
- anaerobic digestion